Aethlon Medical IncAEMD
Price$6.52

Qualitative Analysis

Business overview

Business Overview

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. The company's core technology is the Hemopurifier®, an investigational extracorporeal medical device designed to selectively bind and remove harmful exosomes, extracellular vesicles (EVs), and circulating viruses from the bloodstream. By depleting these target particles, the Hemopurifier aims to address unmet clinical needs in oncology (by removing immunosuppressive tumor-derived exosomes) and infectious diseases (including severe viral pathogens and Long COVID).

Research as of 20 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Hemopurifier Clinical Development in OncologyInnovation

Advancing the Hemopurifier, a first-in-class therapeutic device designed to deplete cancer-promoting exosomes, through safety, feasibility, and dose-finding clinical trials in Australia for patients with solid tumors.

Expected impact: Establish safety, feasibility, and optimal dosing of the Hemopurifier when used in combination with pembrolizumab (Keytruda) or nivolumab (Opdivo).

Sign in / Sign up to read more
InvestmentSupported by existing cash reserves of approximately $5.0 million as of March 31, 2026, supplemented by $1.85 million raised post-fiscal year-end.
TimelineOngoing, with Cohort 3 initiated in June 2026.
Preclinical Platform ExpansionGrowth

Evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis, chronic kidney disease, and Long COVID extracellular vesicles (EVs).

Expected impact: Broaden the potential addressable market and establish the Hemopurifier as a multi-indication therapeutic platform.

Sign in / Sign up to read more
InvestmentPart of the ongoing lean R&D budget ($1.91 million spent on R&D in fiscal 2026).
TimelineOngoing preclinical phase.
Intellectual Property Portfolio StrengtheningInnovation

Securing and expanding patent protections for the Hemopurifier platform, including recently issued patents in the US and Europe covering coronavirus-related conditions and Long COVID.

Expected impact: Enhance long-term platform value and protect proprietary technology against competitors.

Sign in / Sign up to read more
InvestmentIncluded in general administrative and legal expenditures.
TimelinePatents issued during fiscal 2026, extending protection into the 2040s.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

Maxim Group LLCFinancial Advisory Engagement

Engaged as exclusive financial advisor to assist the Board of Directors in evaluating a range of strategic opportunities, including potential partnerships, mergers, acquisitions, or other transactions following preliminary inbound interest.

Terms: Terms of the advisory engagement were not publicly disclosed.

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.